Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of treatments for addictions and related disorders. Co.'s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Co.'s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Co.'s companion diagnostic genetic test. The ADIL average annual return since 2018 is shown above.
The Average Annual Return on the ADIL average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADIL average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADIL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ADIL Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
